Century Therapeutics (IPSC) aims at a durable “once-and-done” Type 1 diabetes cure with hypoimmune iPSC beta cells; runway to ...
Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:00 AM ESTCompany ParticipantsRoopal Thakkar - ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
PYRUKYND® (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME™ (mitapivat) for ...
Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Six months ...
News Medical on MSN
Beta arrestin 1 emerges as key driver of pulmonary hypertension
Researchers have uncovered the pivotal role of a previously overlooked protein in the development of the serious illness.
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.
Persistent inflammation may influence neurodegeneration through microglial activation, yet evidence remains hypothesis driven ...
CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...
PYRUKYND (mitapivat) worldwide net revenues of $20.0 million in fourth quarter and $54.0 million for full yearAQVESME (mitapivat) for thalassemia now available in U.S. following FDA approvalCompany wi ...
From prevention to precision medicine, researchers aim to translate scientific breakthroughs into better patient outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results